Nov. 22 at 11:06 PM
$CLDI Accomplished executives like Mace Rothenberg—experienced in oncology and drug development—do not typically join boards of companies that are clearly on the verge of bankruptcy. Instead, they often lend their expertise to promising or early-stage ventures in biotech and pharma, where there's potential for growth, innovation, or successful drug approvals, aligning with their professional reputations and networks. While biotech is inherently risky, with over 90% of drug candidates failing and many startups shuttering, board members usually join based on scientific merit or market potential rather than stepping into known financial distress.
